Morphogenesis, Inc.
Morphogenesis, Inc.
  • Home
    • Scientific Overview
    • Publications
    • Pipeline
    • Clinical Trials
    • Our Philosophy
    • Our Team
    • Our Executive Board
    • Our Intellectual Property
    • Our Bio Facility
    • Newsroom
    • Home
    • Our Science
      • Scientific Overview
      • Publications
    • Clinical Trials
      • Pipeline
      • Clinical Trials
    • About Us
      • Our Philosophy
      • Our Team
      • Our Executive Board
      • Our Intellectual Property
      • Our Bio Facility
      • Newsroom
  • Home

Clinical Trials

image60

Phase 1 Melanoma

Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected). These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-7 business days for any delayed adverse events.

ClinicalTrials.gov Identifier: NCT03655756 (completed)

Find out more

Phase 1 Merkel Cell or Squamous Cell Carcinomas

In this clinical phase I, non-randomized, open-label, uncontrolled, interventional, multi-center trial, 20 adult subjects (≥ 18 years of age) with advanced Merkel cell carcinoma (MCC) or cutaneous squamous cell carcinoma (cSCC) will receive a fixed dose of 0.1 mg of IFx-Hu2.0 intralesionally as monotherapy in up to three lesions at up to three time points. Subjects will be observed for any acute adverse events (AEs) post injection and for any delayed AEs at Day 28, 35 and/or 42 ± 7 days, depending on the cohort (exposure escalation and expansion design).

ClinicalTrials.gov Identifier: NCT04160065 (recruiting)

Find out more

Phase 2 Melanoma

This is an open-label, multi-site, non-controlled, interventional, randomized phase 2 trial of IFx-Hu2.0 ± PD-1 antagonist for the treatment of patients with stage III to IV cutaneous melanoma who are primarily (i.e. no response) or secondarily (i.e. progression) refractory to at least 1 cycle (i.e. 12 weeks) of an FDA-approved PD-1 antagonist therapy per the respective, current label.

Currently under IRB Review.

Find out more

Copyright © 2021 Morphogenesis, Inc. - All Rights Reserved.

Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept